Feed / RLAY

Relay Therapeutics, Inc.

RLAY

Healthcare · 20.33 +8.5% today

Participation confirmed · construction unavailableMarket checked 20 Aug, 09:30 GMT-4

Jodie situation report

Relay Therapeutics, Inc.'s move is spreading beyond its market group.

No new filing conclusion is available. 23 of 23 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 8 directly disclosed connections are confirming.

Company+8.5% todayVolume comparison unavailable
Market group23 of 23 activeClinical Biotechnology · active
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 15 of 23 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • BMRN remains aligned with the group in the next market snapshot.

Invalidation: The live read weakens if participation falls to 8 of 23 members or fewer.

Watch this read

Who this business touches

The relationships behind RLAY

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

PFEPfizer, Inc.partnerFeb 26, 2026

We are also advancing triplet combination arms with zovegalisib, fulvestrant and cyclin dependent kinase 4/6, or CDK 4/6, inhibitors, or atirmociclib, the investigative selective-CDK4 inhibitor from Pfizer Inc., or Pfizer.

AZNAstraZeneca PLCcompetitorFeb 26, 2026

Zovegalisib– Breast Cancer and Solid Tumors We expect that zovegalisib will compete against approved medicines, Piqray (alpelisib), a non-selective PI3Kα inhibitor marketed by Novartis for the treatment of PIK3CA mutated HR+, HER2- advanced or metastatic brea…

Depended on by

ABSIAbsci CorporationcompetitorNov 12, 2025

AI-enabled small molecule design) that may seek to develop antibody design capabilities, such as Recursion Pharmaceuticals, Inc., Relay Therapeutics, Inc., Isomorphic Labs Limited, and Schrodinger, Inc., among others; and; • we may face competition from acade…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

RLAY is currently a Participant in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.